Allspring Global Investments Holdings LLC Has $5.86 Million Holdings in Immunocore Holdings plc (NASDAQ:IMCR)

Allspring Global Investments Holdings LLC trimmed its holdings in shares of Immunocore Holdings plc (NASDAQ:IMCR - Free Report) by 21.0% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 85,784 shares of the company's stock after selling 22,867 shares during the period. Allspring Global Investments Holdings LLC owned about 0.18% of Immunocore worth $5,861,000 at the end of the most recent reporting period.

Several other hedge funds have also modified their holdings of the business. Legato Capital Management LLC raised its position in Immunocore by 61.7% in the fourth quarter. Legato Capital Management LLC now owns 7,235 shares of the company's stock worth $494,000 after acquiring an additional 2,762 shares in the last quarter. Graham Capital Management L.P. purchased a new stake in Immunocore in the 3rd quarter valued at approximately $411,000. Qube Research & Technologies Ltd boosted its stake in shares of Immunocore by 102.0% during the third quarter. Qube Research & Technologies Ltd now owns 125,199 shares of the company's stock valued at $6,498,000 after acquiring an additional 63,232 shares during the last quarter. Exchange Traded Concepts LLC raised its stake in Immunocore by 34.0% in the 4th quarter. Exchange Traded Concepts LLC now owns 2,656 shares of the company's stock valued at $181,000 after purchasing an additional 674 shares during the last quarter. Finally, FMR LLC raised its stake in Immunocore by 4.4% in the 3rd quarter. FMR LLC now owns 2,136,223 shares of the company's stock valued at $110,870,000 after purchasing an additional 90,116 shares during the last quarter. 84.50% of the stock is owned by institutional investors and hedge funds.

Immunocore Stock Up 1.7 %

Shares of IMCR traded up $0.94 during midday trading on Friday, reaching $55.68. 447,723 shares of the company were exchanged, compared to its average volume of 489,212. The stock has a 50-day moving average price of $63.75 and a 200-day moving average price of $60.29. The company has a market cap of $2.77 billion, a price-to-earnings ratio of -48.00 and a beta of 0.89. The company has a current ratio of 3.80, a quick ratio of 3.77 and a debt-to-equity ratio of 0.13. Immunocore Holdings plc has a 1-year low of $42.21 and a 1-year high of $76.98.

Immunocore (NASDAQ:IMCR - Get Free Report) last posted its quarterly earnings data on Wednesday, February 28th. The company reported ($0.40) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.28) by ($0.12). The firm had revenue of $70.16 million for the quarter, compared to analysts' expectations of $53.25 million. Immunocore had a negative net margin of 22.48% and a negative return on equity of 15.78%. The company's revenue for the quarter was up 22.4% on a year-over-year basis. During the same quarter in the prior year, the business earned ($0.63) EPS. Research analysts expect that Immunocore Holdings plc will post -1.54 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several research analysts have weighed in on IMCR shares. JPMorgan Chase & Co. boosted their price target on Immunocore from $60.00 to $70.00 and gave the company an "overweight" rating in a report on Wednesday, March 20th. HC Wainwright restated a "buy" rating and issued a $90.00 price target on shares of Immunocore in a report on Wednesday, March 6th. Mizuho increased their price objective on shares of Immunocore from $86.00 to $90.00 and gave the stock a "buy" rating in a report on Tuesday, March 5th. Oppenheimer reissued an "outperform" rating and issued a $87.00 target price (up from $85.00) on shares of Immunocore in a research report on Thursday, February 29th. Finally, Canaccord Genuity Group upped their price target on shares of Immunocore from $60.00 to $63.00 and gave the stock a "hold" rating in a research report on Thursday, February 29th. Two investment analysts have rated the stock with a hold rating and ten have issued a buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $80.55.

Immunocore Company Profile

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.